Treace Medical Concepts, Inc.
TMCI
$7.47
-$0.23-2.99%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 213.75M | 210.82M | 209.36M | 202.86M | 198.53M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 213.75M | 210.82M | 209.36M | 202.86M | 198.53M |
| Cost of Revenue | 42.50M | 41.64M | 41.09M | 39.33M | 38.38M |
| Gross Profit | 171.25M | 169.18M | 168.26M | 163.53M | 160.16M |
| SG&A Expenses | 197.92M | 200.59M | 203.36M | 206.27M | 206.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 261.59M | 263.07M | 264.99M | 265.13M | 263.48M |
| Operating Income | -47.84M | -52.25M | -55.64M | -62.27M | -64.95M |
| Income Before Tax | -49.18M | -52.99M | -55.74M | -61.52M | -63.68M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.18 | -52.99 | -55.74 | -61.52 | -63.68 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.18M | -52.99M | -55.74M | -61.52M | -63.68M |
| EBIT | -47.84M | -52.25M | -55.64M | -62.27M | -64.95M |
| EBITDA | -39.41M | -44.28M | -48.22M | -54.82M | -58.09M |
| EPS Basic | -0.79 | -0.85 | -0.90 | -0.99 | -1.03 |
| Normalized Basic EPS | -0.49 | -0.53 | -0.56 | -0.62 | -0.64 |
| EPS Diluted | -0.79 | -0.85 | -0.90 | -0.99 | -1.03 |
| Normalized Diluted EPS | -0.49 | -0.53 | -0.56 | -0.62 | -0.64 |
| Average Basic Shares Outstanding | 250.24M | 249.31M | 248.44M | 247.80M | 247.14M |
| Average Diluted Shares Outstanding | 250.24M | 249.31M | 248.44M | 247.80M | 247.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |